Red Blood Cell Transfusion Clinical Trial
— iTADSOfficial title:
An Innovative Trial Assessing Donor Sex on Recipient Mortality (iTADS)
Verified date | June 2022 |
Source | Ottawa Hospital Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The iTADS trial will test an important blood donor characteristic - donor sex - to see whether male donor blood leads to a greater benefit for transfusion recipients compared to female donor blood. The trial will help determine how the investigators can tailor the selection of blood donors based on donor characteristics (e.g. sex) to further improve the safety and optimize the clinical benefit of blood products in Canada.
Status | Active, not recruiting |
Enrollment | 8850 |
Est. completion date | December 1, 2022 |
Est. primary completion date | January 23, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - All patients (excluding neonates) requiring one or more allogeneic RBC transfusions for the treatment of anemia will be included. Exclusion Criteria: - Patients that do not have a valid Ontario Health Insurance Plan (OHIP) number at time of first transfusion - Patients that require emergent release of a RBC transfusion and in whom emergency randomization could not be completed - Patients with complex antibody profile in which it is impossible to match RBC units |
Country | Name | City | State |
---|---|---|---|
Canada | Ottawa Hospital - General Campus | Ottawa | Ontario |
Lead Sponsor | Collaborator |
---|---|
Ottawa Hospital Research Institute | Canadian Blood Services, Canadian Institutes of Health Research (CIHR) |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Survival | Measured from date of first randomization to date of death or end of study 2 years from first patient enrollment. | 2 years | |
Secondary | Survival | Measured from date of first randomization to date of death or end of study 2 years from the first patient enrollment. | 30 days, 3 months, 6 months and 1 year | |
Secondary | Length of hospital stay | Number of days admitted to hospital for the treatment of anemia. | 2 years | |
Secondary | New ICU admission | Occurrence of ICU admission(s) once discharged for the treatment of anemia. | 2 years | |
Secondary | Re-hospitalization | Occurrence of additional hospital admission(s) once discharged for the treatment of anemia. | 2 years | |
Secondary | Health system costs | The cost of the treatment of anemia and any related downstream health care resources. | 2 years | |
Secondary | Occurrence of new cancer | The number of new cancer diagnoses, not present during the initial treatment of anemia. | 2 years | |
Secondary | Recurrence of cancer | The number of repeat cancer diagnoses, diagnosed previous to the initial treatment of anemia. | 2 years | |
Secondary | Infection rates | Methicillin-resistant Staphylococcus aureus and Clostridium difficile for hospital-acquired infections. | 2 years | |
Secondary | New occurrence of hemodialysis | For severe chronic renal failure. | 2 years | |
Secondary | Myocardial infarctions | For cardiac events. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06230198 -
The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery
|
N/A | |
Recruiting |
NCT04757909 -
Detection of Anemizations in Primary Care.
|
N/A | |
Terminated |
NCT02566577 -
Physiologic Effects of RBC Transfusion
|
Phase 4 | |
Recruiting |
NCT04920045 -
A Trial to Assess the Effect of Transfusion Strategies on Fatigability Levels After Hospital Discharge
|
N/A | |
Completed |
NCT01258010 -
Impact of Tranexamic Acid on Red Blood Cell Transfusion in Spinal Surgery
|
N/A | |
Recruiting |
NCT05405426 -
Trial of Indication-Based Transfusion of Red Blood Cells in ECMO
|
N/A | |
Completed |
NCT05798130 -
Assessment of Oxygen Extraction Rate Changes Following Red Blood Cell Transfusion in the Intensive Care Unit
|